William Blair Weighs in on Amgen's Q2 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN - Free Report) - William Blair raised their Q2 2025 EPS estimates for Amgen in a report issued on Monday, July 14th. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings per share of $5.21 for the quarter, up from their prior forecast of $5.16. William Blair has a "Outperform" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period last year, the company posted $3.96 EPS. The business's quarterly revenue was up 9.4% on a year-over-year basis.

A number of other analysts have also recently issued reports on the company. Guggenheim started coverage on Amgen in a report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 target price for the company. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Mizuho raised their target price on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Finally, Royal Bank Of Canada reduced their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of "Hold" and a consensus price target of $307.82.

Amgen Stock Performance

Amgen stock opened at $292.51 on Wednesday. The company has a market cap of $157.29 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 2.68 and a beta of 0.49. Amgen has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. The stock's 50-day moving average is $284.34 and its 200-day moving average is $288.57.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.69% of the stock is owned by corporate insiders.

Institutional Trading of Amgen

Several institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Amgen by 35.0% in the 4th quarter. Proficio Capital Partners LLC now owns 1,806 shares of the medical research company's stock valued at $471,000 after acquiring an additional 468 shares during the last quarter. Madison Investment Advisors LLC acquired a new stake in shares of Amgen during the 4th quarter valued at approximately $1,948,000. Creative Financial Designs Inc. ADV raised its position in shares of Amgen by 2.9% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 5,300 shares of the medical research company's stock valued at $1,381,000 after acquiring an additional 151 shares in the last quarter. Finally, 1ST Source Bank lifted its stake in Amgen by 4.0% during the fourth quarter. 1ST Source Bank now owns 2,988 shares of the medical research company's stock worth $779,000 after purchasing an additional 116 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.